MA34525B1 - Nouveau conjugué de facteur de croissance hématopoïétique g-csf et de polyéthylène glycol - Google Patents

Nouveau conjugué de facteur de croissance hématopoïétique g-csf et de polyéthylène glycol

Info

Publication number
MA34525B1
MA34525B1 MA35731A MA35731A MA34525B1 MA 34525 B1 MA34525 B1 MA 34525B1 MA 35731 A MA35731 A MA 35731A MA 35731 A MA35731 A MA 35731A MA 34525 B1 MA34525 B1 MA 34525B1
Authority
MA
Morocco
Prior art keywords
csf
growth factor
conjugate
hematopoietic growth
polyethylene glycol
Prior art date
Application number
MA35731A
Other languages
English (en)
Inventor
Dmitriy Valentinovich Morozov
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Elena Leonidovna Morozova
Tatyana Veniaminovna Chernovskaya
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34525(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of MA34525B1 publication Critical patent/MA34525B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES AGENTS PHARMACEUTIQUES ET UN MÉDICAMENT, À SAVOIR, DE NOUVEAUX CONJUGUÉS PHYSIOLOGIQUEMENT ACTIFS DU FACTEUR DE CROISSANCE HÉMATOPOÏÉTIQUE G-CSF REPRÉSENTÉ PAR LA FORMULE GÉNÉRALE (I) DANS LAQUELLE : N DÉSIGNE DES ENTIERS DE 681 À 1 000; M DÉSIGNE UN ENTIER > 4; NAH-G-CSFDÉSIGNE UN POLYPEPTIDE NATUREL OU RECOMBINANT, AYANT L'ACTIVITÉ DE G-CSF. L'INVENTION CONCERNE EN OUTRE DES MÉDICAMENTS CONTENANT LE CONJUGUÉ DE FORMULE (I) REVENDIQUÉ, DES COMPOSITIONS PHARMACEUTIQUES, L'UTILISATION D'UN CONJUGUÉ DE FORMULE (I) POUR DES AGENTS PHARMACEUTIQUES ET DES MÉDICAMENTS PRÉSENTANT LE FACTEUR DE CROISSANCE HÉMATOPOÏÉTIQUE G-CSF EN TANT QUE SUBSTANCE ACTIVE, DES APPROCHES POUR PRÉVENIR ET/OU TRAITER LA NEUTROPÉNIE, LE CONTENANT QUI COMPREND LA COMPOSITION PHARMACEUTIQUE.
MA35731A 2010-08-13 2011-07-19 Nouveau conjugué de facteur de croissance hématopoïétique g-csf et de polyéthylène glycol MA34525B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (ru) 2010-08-13 2010-08-13 Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
PCT/RU2011/000532 WO2012021088A1 (fr) 2010-08-13 2011-07-19 Nouveau conjugué de facteur de croissance hématopoïétique g-csf et de polyéthylène glycol

Publications (1)

Publication Number Publication Date
MA34525B1 true MA34525B1 (fr) 2013-09-02

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35731A MA34525B1 (fr) 2010-08-13 2011-07-19 Nouveau conjugué de facteur de croissance hématopoïétique g-csf et de polyéthylène glycol

Country Status (18)

Country Link
KR (1) KR101549457B1 (fr)
CN (1) CN103140499B (fr)
CL (1) CL2013000400A1 (fr)
CO (1) CO6670557A2 (fr)
CR (1) CR20130020A (fr)
CU (1) CU24139B1 (fr)
DO (1) DOP2013000003A (fr)
EA (1) EA019043B1 (fr)
EC (1) ECSP13012399A (fr)
MA (1) MA34525B1 (fr)
MY (1) MY160732A (fr)
NI (1) NI201300007A (fr)
PE (1) PE20131085A1 (fr)
PH (1) PH12012502426A1 (fr)
RS (1) RS20130094A1 (fr)
RU (1) RU2446173C1 (fr)
SG (1) SG187572A1 (fr)
WO (1) WO2012021088A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (fr) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Kits de sécurité de céfuroxime
NZ702415A (en) 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN103908427B (zh) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法
RU2535002C2 (ru) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법
JP6742300B2 (ja) 2014-07-14 2020-08-19 ジェンノヴァ バイオファーマシューティカルズ リミテッド ｒＨｕ−ＧＣＳＦの精製のための新規プロセス
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
CN115297844A (zh) * 2020-03-17 2022-11-04 德拉格雷丘尔公司 用于吸入的gm-csf的液体制剂
JP2023518412A (ja) * 2020-03-20 2023-05-01 アムジェン インコーポレイテッド 酸性プロテアーゼを使用するペグフィルグラスチムの遊離ｎ末端の決定

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401384B1 (fr) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (ko) * 2003-03-21 2004-10-01 한미약품 주식회사 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
RU2278870C2 (ru) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения, и иммунобиологическое средство на его основе
MX2008009125A (es) * 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
EP2044097A4 (fr) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc Ribonucléases modifiées

Also Published As

Publication number Publication date
DOP2013000003A (es) 2013-07-31
PH12012502426A1 (en) 2021-06-02
CR20130020A (es) 2013-02-20
EA019043B1 (ru) 2013-12-30
SG187572A1 (en) 2013-03-28
RU2446173C1 (ru) 2012-03-27
RS20130094A1 (sr) 2013-08-30
MY160732A (en) 2017-03-15
CL2013000400A1 (es) 2013-07-26
KR101549457B1 (ko) 2015-09-02
PE20131085A1 (es) 2013-10-10
EA201101035A1 (ru) 2012-02-28
ECSP13012399A (es) 2013-05-31
CU24139B1 (es) 2015-12-23
NI201300007A (es) 2014-05-26
CO6670557A2 (es) 2013-05-15
CN103140499B (zh) 2014-12-17
WO2012021088A1 (fr) 2012-02-16
CU20130012A7 (es) 2013-04-19
CN103140499A (zh) 2013-06-05
KR20130043167A (ko) 2013-04-29

Similar Documents

Publication Publication Date Title
MA34525B1 (fr) Nouveau conjugué de facteur de croissance hématopoïétique g-csf et de polyéthylène glycol
Falanga et al. Peptides and dendrimers: How to combat viral and bacterial infections
Singh et al. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with ‘standard of care’medicinal and procedures not requiring regulatory approval for use
NZ581589A (en) Solubilized sterile injectable formulation of docetaxel without Tween 80
US20090137527A1 (en) Compositions and methods for modulating immune function
MA38544A1 (fr) Compositions de principes pharmaceutiques actifs contenant de l'éther de monoéthyle et de diéthylèneglycol ou d'autres dérivés alkyliques
RU2013121788A (ru) Ингибиторы репликации вич
MA33608B1 (fr) Composition pharmaceutique, forme galenique, procede pour leur preparation, methodes de traitement et leurs utilisations
JP6806685B2 (ja) 急性放射線症候群を治療するための組成物及び方法
MY168784A (en) The new stable polyethylene glycol conjugate of interferon alpha,represented by one positional isomer
Li et al. Effects of green tea extract epigallocatechin-3-gallate on oral diseases: a narrative review
EP2743275A4 (fr) Composition pharmaceutique contenant un extrait de chèvrefeuille et des antibiotiques, kit pharmaceutique, et utilisation de l'extrait de chèvrefeuille pour la préparation d'un médicament
US20170000762A1 (en) Anti-microbial composition
NZ702342A (en) Pharmaceutical formulation
ES2600469T3 (es) Un compuesto para su uso en el tratamiento de lesiones asociadas con la exposición al gas fosgeno o al gas de cloro
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
RS53546B1 (sr) Kompozicija za inhibiranje inflamacije koja se sastoji od hijaluronske kiseline i inhibitora hmg-coa reduktaze
FR2900404B1 (fr) Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
MX2023001572A (es) Formas farmaceuticas sólidas de palbociclib.
KR101585795B1 (ko) 활성 성분으로 디에칠렌글라이콜모노벤질에텔을 함유하는 보존제 조성물
Ismaiel et al. Modulation of nephrotoxicity induced by gentamicin with bone marrow mesenchymal stem cells and moringa oleifera extract
Brahmkshatriya et al. Recent developments in the treatment of atherosclerosis
JP2011246432A (ja) Ｃ型肝炎の予防及び／又は治療のための医薬
US20230372264A1 (en) Composition for the prevention of infection by sars-cov-2
Kaur et al. Novel antioxidant protein target therapy to counter the prevalence and severity of SARS-CoV-2